ArticleFrontiers in endocrinology2026
Androgen profiling in adolescent girls with polycystic ovary syndrome.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To characterize global steroid hormone dysregulation and the androgen profile in adolescent girls with polycystic ovary syndrome (PCOS), and to explore adrenal versus ovarian androgen origins using a dexamethasone suppression test combined with liquid chromatography-tandem mass spectrometry (LC-MS/MS). Methods: We consecutively enrolled 37 adolescent PCOS patients and 22 age-matched healthy controls. PCOS diagnosis followed the 2023 international evidence-based recommendations. All participants underwent clinical evaluation and LC-MS/MS steroid profiling; 24 PCOS patients also received a dexamethasone suppression test. Results: Compared with healthy controls, the PCOS group had elevated levels of multiple androgens, including dehydroepiandrosterone (DHEA), dehydroepiandrosterone sulfate (DHEA-S), androstenedione (AD), total testosterone (TT), androsterone (ADT), dihydrotestosterone (DHT), 11β-hydroxyandrostenedione (11-OHAD), 11β-hydroxytestosterone (11-OHT), and epitestosterone (EpiT), as well as estrone, pregnenolone, and 17-hydroxyprogesterone, along with decreased sex hormone-binding globulin (SHBG). Spearman correlation showed that DHEA-S explained only limited variation in 11-OHAD (r Conclusion: Adolescent girls with PCOS exhibit widespread androgen abnormalities. FAI demonstrates the highest diagnostic value, and the addition of total testosterone and androstenedione modestly improves detection. The dexamethasone suppression test suggests that most 11-oxygenated androgens are of adrenal origin, whereas testosterone suppression is minimal. Elevated DHEA-S levels are not consistently aligned with adrenal-origin androgen dominance defined by the suppression test. These findings warrant further validation in larger populations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.